Envoy Medical Inc

This advisory proposal requests stockholders to approve, on a non-binding basis, the overall compensation of named executive officers as disclosed in the proxy. Management frames pay programs as aligning executives with stockholder interests and rewarding performance. The vote is advisory and not binding; the Board and Compensation Committee intend to consider the outcome when setting future compensation but are not obligated to change pay practices. The disclosure includes base salary, bonuses, option awards, and other compensation, and the company highlights its intention to align incentives with business objectives. A significant negative vote would prompt review by the Board and Compensation Committee. The context includes ongoing recruitment and retention needs for a small medical device company and the potential dilution from equity awards; investors may weigh pay-for-performance metrics, equity burn, and governance practices in evaluating the proposal.

The management proposal seeks shareholder approval to increase the 2023 Equity Incentive Plan pool by 6,000,000 shares (from 4,000,000 to 10,000,000). Management argues the expansion is necessary due to significant dilution from recent financings and to preserve the company’s ability to attract, motivate, and retain employees, directors and consultants through equity-based incentives. The proposal would meaningfully increase potential future equity dilution (company estimates the full 10,000,000 would be ~11.5% of issued and outstanding shares), and the administrator would retain broad discretion over grant terms, repricing and repurchases. The plan includes standard adjustment provisions and permits various award types, including options, RSUs, performance awards, and repricing with participant consent; the Compensation Committee administers the plan. Shareholders should consider the trade-offs between dilution and the necessity of equity incentives for a small med-tech company's growth and recruiting. If approved, a new Form S-8 registration will be filed for the additional shares. The board recommends voting FOR due to competitive and operational imperatives, but investors may evaluate equity burn rate, grant practices, and governance features like repricing authority when assessing the proposal.

Management seeks shareholder approval to increase the ESPP reserve by 1,200,000 shares to support employee purchases for an estimated two-year period. The ESPP is positioned as an employee retention and recruitment tool, offering discounted purchases (typically 85% of market) with semiannual offering periods. Management notes that without the increase, shares under the ESPP could be exhausted by May 2026, undermining compensation competitiveness. The administrator (Compensation Committee) has broad discretionary authority over offerings and pricing mechanics. Investors should weigh the dilution effect versus the benefits of employee alignment and retention, the discount level, potential tax treatment implications, and the company’s employee headcount growth assumptions. Board recommends FOR; the proposal will be binding if approved.

Management requests shareholder approval under Nasdaq Rule 5635(d) to permit exercisability of 123,750,000 warrants issued in connection with a February 12, 2026 offering. The transaction already occurred; this vote concerns only approval for the issuance of underlying shares upon exercise. Approving would allow warrant holders to exercise and the company to receive up to ~$49.9 million in gross proceeds at the stated exercise prices, while disapproving would prevent exercise and require the company to repeatedly seek approval every 90 days until approved or warrants expire, incurring costs and operational uncertainty. The issuance would cause significant dilution (potentially increasing outstanding shares materially—management notes full exercise would add 123.75M shares), with attendant adverse impacts on existing holders and potential downward pressure on share price. Company insiders and a 37.8% holder (Glen Taylor) participated in the offering and hold substantial warrants and have agreed to vote shares in favor via a Voting and Warrant Extension Agreement, creating a high likelihood of approval if the Board recommends it. Investors should assess the trade-off between needed capital access and substantial dilution, examine the warrants’ exercise terms and milestone triggers (FDA application/approval tied milestones), and consider governance impacts of related-party participation. The Board unanimously recommends FOR the Issuance Proposal.